L-propionyl carnitine reduces toxicity correlated to cyclosporine-induced intracellular ATP concentrations

Drugs under Experimental and Clinical Research

Volumn 25, Issue 4, 1999, Pages 173-177

  Giovannini, Luca ^a   Migliori, M ^b   De Pietro, S ^b   Taccola, D ^b   Panichi, V ^b   Bertelli, A A E ^b   Bertelli, A ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CYCLOSPORIN; PROPIONYLCARNITINE;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; EXPERIMENT; KIDNEY INJURY; KIDNEY PERFUSION; MALE; NONHUMAN; RAT; VASCULAR RESISTANCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOTONIC AGENTS; CARNITINE; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY CORTEX; MALE; RATS; RATS, WISTAR;

EID: 0032839008     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Myers B. D. The long-term coarse of cyclosporine associated chronic nephropathy. Kidney Int., 33, 590, 1998.
2. McNally P.G, Feemally J. Pathophysiology of cyclosporin A nephrotoxicity. Experimental and clinical observation. Nephrol. Dial. Transplant., 7, 791, 1992.
3. Rintmalm G.B., Twatsuki S., Stazel T.E. Nephrotoxicity of cyclosporin A in liver and kidney transplantation patients. Lancet, 1, 470, 1981.
4. Bertelli A., Giovannini L., Palla R., Migliori M., Panichi V., Andreini B. Protective effect of L-propionyl carnitine on cyclosporine induced nephrotoxicity. Drugs. Exptl. Clin. Res., 21 (6), 221, 1995.
5. Paulson D.J., Traxler Y., Schidt M., Shung A.L. Protection of the ischaemia myocardium by L-propionyl carnitine effects on the recovery of cardiac reperfusion, carnitine transport and fatty acid oxidation. Cardiovasc. Res., 20, 536, 1966.
6. Bertelli A., Giovannini L., Bertelli A.A.E. Inhibition of histamine release and pressure increase induced by endothelin (ET-1) in isolated rat kidneys treated with propionyl carnitine. Drugs. Exptl. Clin. Res., 18(8), 349, 1992.
7. Giovannini L., Palla R., Bertelli A.A.E., et al. Cyclosporine nephrotoxicity evaluated by tissue calcium deposition is prevented by L-propionyl carnitine in isolated perfused rat kidney. Transplant. Proc., 28, 3122, 1996.
8. Gunter T.E., Gunter K.K., Shou S.S. Mitochondrial calcium transfer. Physiological nd pathological relevance. Am. J. Physiol., 267, C313, 1994.
9. Shure K.H.J., Brecht Y.P., Lohfert H. The basic requirement of the function of the isolated free perfused rat kidney. Delugers Arch., 35, 4, 1975.
10. Maack P. Renal clearance and isolated kidney infusion technique. Kidney Int., 30, 142, 1986.
11. 2 after warm ischaemia. Am. J. Physiol., 247 (6 Pt 2), R1047, 1984.
12. Fournier N., Ducet G., Crevat A. Action of cyclosporin A on mitochondrial calcium fluxes. J. Biolnerv. Biomembr., 19, 297,1987.
13. Tuena De Gomes-Puyon M., Lars Ernster A. Control of activity states of heart rnitochondrial ATP-ase. Role of the proton-motive force and Ca++. Biochim. Biophys. Acta., 592, 396, 1980.
14. Salducci D., Chauvet-Manges A.M., Crevat A. The restoration of ATP synthesis may explain the protective effect of calcium antagonists against cyclosporin A nephrotoxicity. Life Sci., 50, 2053, 1993.
15. Shaw L.M., Kaplan B., Kaufman D. Toxic effects of immunosuppressive drugs mechanisms and strategies for controlling them. Clin. Chem., 42, 1316, 1996.
16. Jiang T., Acosta D. Mitochondrial Ca++ overload in primary cultures of fat renal cortical epithelial cells by cytotoxic concentrations of cyclosporine. Toxicology, 95, 155, 1993.
17. Schrier R.W., Arnold P.E., Van Patten V.J., et al. Cellular calcium in ischemie acute renal failure: Role of calcium entry blockers. Kidney Int., 31, 313, 1987.
18. Rego A., Vargas R., Sucrez K.R. Mechanism of cylosporine potentatbn of vasoconstriction of the isolated rat mesentric arterial bed: Role of extracellular calcium. J. Pharmacol. Exp. Ther., 254, 799,1990.
19. Hay R., Tammi K., Riffel B. Alterations in molecular structure of renal mitochondria associated with cyclosporin A treatment. Clin. Nephrol., 35, 923, 1986.
20. Salducci M.D., Chaivet-Monges A.M., Tillement J.P., Crevat P. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporin A in isolated rat liver mitochondria. J. Pharmacol. Expt. Ther., 277, 417, 1966.
21. Pfeilschifter J. Cyclosporin A augments vasoconstrictor-induced rise in intracellular free calcium in rat renal mesangial cells. Biochem. Pharmacol., 37, 4205, 1988.
22. Kirk A.J.B., Omar L, Dark Y.H. Long-term improvement in renal function using mifedipine in cyclosporine-associated hypertension. Transplant., 50, 1061, 1990.
23. Pestana M., Viera-Coelho M.A. et al. Assessment of renal dopaminergic system activity during cyclosporin A administration in the rat. Br. J. Pharmacol., 115, 1349, 1995.
24. Remuzzi G., Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am. J. Kidney Dis., 13, 241, 1989.
25. Bunchman T.E., Brookshire CA Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. Clin. Invest., 88, 310, 1991.
26. Gardner M.P., Houghton D.C., Bennet W.M. Clinically relevant doses and blood leveis produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplant., 61, 1506, 1996.
27. Bertelli A., Bertelli A.A.E., Giovannini L. The potentiating effect of propionyl camitine on prostacycline prevention of thrombosis induced by endothelin (ET-1) and K-carrageenin. Drugs Exptl. Clin. Res.,20(1), 7, 1994.
28. Elliot G.R., Lanwsen B.M.P., Bonta L. The effect of acute feeding of carnitine, acetyl carnitine and propionyl carnitine on basal and 123187 stimulated cicosanoid release from rat carrageenin elicited peritoneal macrophages. Br. J. Nutr., 64, 497, 1990.
29. Bertelli A., Conte A., Palmieri L., Ronca G., Segnini D., Yu G. Effect of propionyl carnitine on energy charge and adenine nucleotide content of cardiac endothelial cells during hypoxia. Int. J. Tiss. React., 13(1), 37. 1991.
30. Bertelli A., Conte A., Ronca G., Zucchi R. Effect of propionyl carnitine on cardiac energy metabolism evaluated by the release of purine catabolites. Drugs. Exptl. Clin. Res. 13 (2), 1991.